Featured Research

from universities, journals, and other organizations

Like prostate cancer, bladder cancer patients may benefit from anti-androgen therapy

Date:
September 24, 2012
Source:
University of Colorado Denver
Summary:
Bladder cancer patients whose tumors express high levels of the protein CD24 have worse prognoses than patients with lower CD24. A new study shows that CD24 expression may depend on androgens – and that anti-androgen therapies like those currently used to treat prostate cancer may benefit bladder cancer patients.

Bladder cancer patients whose tumors express high levels of the protein CD24 have worse prognoses than patients with lower CD24. A University of Colorado Cancer Center study published September 24 in the Proceedings of the National Academy of Sciences shows that CD24 expression may depend on androgens -- and that anti-androgen therapies like those currently used to treat prostate cancer may benefit bladder cancer patients.

Related Articles


"This is a major finding -- bladder cancer development and spread to other organs depends significantly on CD24, which in turn depends on androgens like testosterone. By taking away these androgens, we may be able to greatly diminish the proliferative and metastatic power of bladder cancer cells," says the study's senior author, Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center.

Theodorescu and colleagues started with mouse models, showing that mice without the ability to make the protein CD24 had fewer primary bladder tumors and metastases (bladder tumor spread to other organs) compared to mice with CD24 intact. This effect was most marked in male mice. The group moved to human tumor samples, showing that when patients were stratified according to the levels of CD24 expressed in their tumors, especially the male patients had poorer outcomes, including higher rates of relapse and shorter disease-free survival.

"To us, these sex-specific findings implied androgen involvement," Theodorescu says. Sure enough, when the group knocked down androgen receptors in human bladder cancer cell lines, they saw a corresponding drop in CD24 levels and also decreased cell proliferation. When they artificially added CD24, cell proliferation resumed regardless of androgen levels. In essence, androgen is effectively a hormonal switch that allowed the harmful effect of CD24 to flow.

Together, these finding imply not only a correlative but a causative effect of CD24 -- that not only do high levels of CD24 mark more aggressive bladder tumors, but that CD24 in fact drives the aggressiveness of these tumors. While the protein CD24 is difficult to affect directly with current therapies, anti-androgen therapies that would diminish the tumor's ability to express CD24 are already in wide use for prostate cancer.

"We hope the results of these studies show the rationale for clinical studies of anti-androgen therapies with bladder cancer, especially in those tumors that happen to test markedly high in CD24 expression," Theodorescu says. "The next step is moving this promising therapy to clinical trials with human patients."


Story Source:

The above story is based on materials provided by University of Colorado Denver. Note: Materials may be edited for content and length.


Cite This Page:

University of Colorado Denver. "Like prostate cancer, bladder cancer patients may benefit from anti-androgen therapy." ScienceDaily. ScienceDaily, 24 September 2012. <www.sciencedaily.com/releases/2012/09/120924152532.htm>.
University of Colorado Denver. (2012, September 24). Like prostate cancer, bladder cancer patients may benefit from anti-androgen therapy. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2012/09/120924152532.htm
University of Colorado Denver. "Like prostate cancer, bladder cancer patients may benefit from anti-androgen therapy." ScienceDaily. www.sciencedaily.com/releases/2012/09/120924152532.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins